[go: up one dir, main page]

WO2018016563A1 - Utilisation d'éribuline et d'inhibiteurs des histone désacétylase dans le traitement du cancer - Google Patents

Utilisation d'éribuline et d'inhibiteurs des histone désacétylase dans le traitement du cancer Download PDF

Info

Publication number
WO2018016563A1
WO2018016563A1 PCT/JP2017/026212 JP2017026212W WO2018016563A1 WO 2018016563 A1 WO2018016563 A1 WO 2018016563A1 JP 2017026212 W JP2017026212 W JP 2017026212W WO 2018016563 A1 WO2018016563 A1 WO 2018016563A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
eribulin
subject
carcinoma
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/026212
Other languages
English (en)
Inventor
Bruce A. Littlefield
Gary HENDLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to EP17831079.3A priority Critical patent/EP3487492A4/fr
Priority to US16/318,198 priority patent/US20190282541A1/en
Priority to JP2019502829A priority patent/JP2019524748A/ja
Publication of WO2018016563A1 publication Critical patent/WO2018016563A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes de traitement et de prévention du cancer (par exemple, un cancer hormonosensible) chez un patient en ayant besoin, par l'administration d'éribuline (par ex, de mésylate d'éribuline) combinée à un dérivé de inhibiteur des histone désacétylase (HDAC).
PCT/JP2017/026212 2016-07-20 2017-07-20 Utilisation d'éribuline et d'inhibiteurs des histone désacétylase dans le traitement du cancer Ceased WO2018016563A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17831079.3A EP3487492A4 (fr) 2016-07-20 2017-07-20 Utilisation d'éribuline et d'inhibiteurs des histone désacétylase dans le traitement du cancer
US16/318,198 US20190282541A1 (en) 2016-07-20 2017-07-20 Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
JP2019502829A JP2019524748A (ja) 2016-07-20 2017-07-20 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364440P 2016-07-20 2016-07-20
US62/364,440 2016-07-20

Publications (1)

Publication Number Publication Date
WO2018016563A1 true WO2018016563A1 (fr) 2018-01-25

Family

ID=60993053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/026212 Ceased WO2018016563A1 (fr) 2016-07-20 2017-07-20 Utilisation d'éribuline et d'inhibiteurs des histone désacétylase dans le traitement du cancer

Country Status (4)

Country Link
US (1) US20190282541A1 (fr)
EP (1) EP3487492A4 (fr)
JP (1) JP2019524748A (fr)
WO (1) WO2018016563A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032769A1 (fr) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Polythérapies comprenant des inhibiteurs de hdac et des inhibiteurs de la tubuline
CN110874403A (zh) * 2018-08-29 2020-03-10 株式会社日立制作所 提问回答系统、提问回答处理方法以及提问回答整合系统
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
WO2022048527A1 (fr) * 2020-09-01 2022-03-10 深圳微芯生物科技股份有限公司 Utilisation de chidamide combiné à un régulateur à la baisse du récepteur des oestrogènes dans le traitement du cancer du sein
US11535670B2 (en) 2016-05-11 2022-12-27 Huyabio International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
US12122833B2 (en) 2016-05-11 2024-10-22 Huyabio International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033656A1 (fr) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Méthodes de traitement du cancer du sein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053991A1 (en) * 2007-11-19 2011-03-03 Gore Lia Treatment of Histone Deacetylase Mediated Disorders
WO2014179738A1 (fr) * 2013-05-03 2014-11-06 Syndax Pharmaceuticals, Inc. Méthodes de traitement du cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033656A1 (fr) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Méthodes de traitement du cancer du sein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BISSONNETTE ET AL.: "The activity of the HDAC inhibitor HBI-8000(Chidamide) combined with eribulin on 4T1 spontaneous metastasis development", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15, May 2017 (2017-05-01), pages e14055, XP009514643, ISSN: 0732-183X, Retrieved from the Internet <URL:http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15suppl.e14055> [retrieved on 20170825], DOI: 10.1200/JCO.2017.35.15_suppl.e14055 *
JAIN,SARIKA ET AL.: "Eribulin mesylate in the treatment of metastatic breast cancer", BIOLOGICS: TARGETS AND THERAPY, vol. 6, 2012, pages 21 - 29, XP055453209 *
See also references of EP3487492A4 *
SWAMI,UMANG ET AL.: "Eribulin-A review of preclinical and clinical studies", CRITICAL REVIEWS IN ONCOLOGY /HEMATOLOGY, vol. 81, 2 March 2011 (2011-03-02), pages 163 - 184, XP028887757 *
T. AI ET AL.: "Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy", CURRENT MEDICINAL CHEMISTRY, vol. 19, no. 4, 2012, pages 475 - 487, XP055406772 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535670B2 (en) 2016-05-11 2022-12-27 Huyabio International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
US12122833B2 (en) 2016-05-11 2024-10-22 Huyabio International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
WO2019032769A1 (fr) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Polythérapies comprenant des inhibiteurs de hdac et des inhibiteurs de la tubuline
CN110874403A (zh) * 2018-08-29 2020-03-10 株式会社日立制作所 提问回答系统、提问回答处理方法以及提问回答整合系统
CN110874403B (zh) * 2018-08-29 2024-03-08 株式会社日立制作所 提问回答系统、提问回答处理方法以及提问回答整合系统
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
WO2022048527A1 (fr) * 2020-09-01 2022-03-10 深圳微芯生物科技股份有限公司 Utilisation de chidamide combiné à un régulateur à la baisse du récepteur des oestrogènes dans le traitement du cancer du sein

Also Published As

Publication number Publication date
US20190282541A1 (en) 2019-09-19
EP3487492A4 (fr) 2020-03-11
JP2019524748A (ja) 2019-09-05
EP3487492A1 (fr) 2019-05-29

Similar Documents

Publication Publication Date Title
EP3487492A1 (fr) Utilisation d&#39;éribuline et d&#39;inhibiteurs des histone désacétylase dans le traitement du cancer
JP2019524748A5 (fr)
ES2728739T3 (es) Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
JP6539345B2 (ja) がん治療のための医薬組成物の調製におけるデュロキセチン塩酸塩薬物の使用
JP2016528162A5 (fr)
RU2014124005A (ru) Комбинация инотузумаба озогамицина и торизела для лечения рака
JP2013522326A5 (fr)
JP2009506054A5 (fr)
JP2017507151A5 (fr)
CA3067065A1 (fr) Tinostamustine destinee a etre utilisee dans le traitement du sarcome
JP2023088996A (ja) 癌治療
JP2015508765A5 (fr)
JP2013528215A5 (fr)
WO2020236667A1 (fr) Procédés de traitement du cancer
US11364237B2 (en) Composition for inhibiting cancer metastasis and treating cancer
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
JP2008516909A5 (fr)
CN104640538B (zh) 包含ndga 衍生物和索拉非尼的组合物以及其在治疗癌症中的用途
Kim et al. Anesthetic considerations for laparoscopy for rectal cancer in patient with amyotrophic lateral sclerosis: a case report
Briker et al. Vertical inhibition of the MAPK pathway as potential treatment strategy in NRAS-mutant melanoma
Yamamoto et al. THU0398 Efficacy of rituximab and other immunosuppressants for IgG4-related disease
JP2019151621A (ja) Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物
Bendale et al. Prognostic significance after use of Rasayana therapy in a colon cancer patient-a case report
Wikerholmen et al. P10. 13. B Repurposing neuroleptics to treat brain metastases: Clozapine as a novel therapy for melanoma brain metastases
Robertson 339 POSTER Identification of XL413, a selective Cdc7 kinase inhibitor which induces cell cycle arrest and exhibits potent antitumor activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17831079

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019502829

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017831079

Country of ref document: EP

Effective date: 20190220